Online citations, reference lists, and bibliographies.

Use Of Proton Pump Inhibitors Increased The Risk Of Hip Fracture: A Population-based Case-control Study.

H. Chiu, Ya-Wen Huang, C. Chang, C. Yang
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE To investigate whether the use of proton pump inhibitor (PPIs) was associated with an increased risk of hip fracture. METHODS We conducted a population-based case-control study in Taiwan. Data were retrospectively collected from the Taiwan National health Insurance Research Database. Cases included all patients with a newly diagnosed of hip fracture in 2005 and 2006 (n = 1241). The controls were pair matched to cases by age, sex, and index date. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by using multiple logistic regression. RESULTS Having been prescribed more than 28 defined daily dose (DDDs) of PPIs was associated with an increased risk for hip fracture in multivariate analyses (adjustments for matching variables and medication use) (at 29-70 DDDs, OR = 1.67, 95% CI = 1.11-2.51 and at >70 DDDs, OR = 2.51, 95% CI = 1.77-3.55). There was a significant trend toward increasing hip fracture risk with increasing cumulative DDDs of PPIs (p for trend <0.0001). CONCLUSIONS This study provides evidence that PPIs use is associated with an increased risk of hip fracture in a dose-response manner.
This paper references
10.1503/cmaj.071330
Use of proton pump inhibitors and risk of osteoporosis-related fractures
L. Targownik (2008)
10.1016/S0899-9007(97)83011-0
Calcium and osteoporosis.
B. Nordin (1997)
10.1016/J.AMJMED.2005.02.007
Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.
M. B. O'Connell (2005)
10.1007/s00198-004-1651-0
High incidence rate of hip fracture in Taiwan: estimated from a nationwide health insurance database
W. C. Chie (2004)
10.1053/J.AJKD.2006.10.007
Epidemiological features of CKD in Taiwan.
Hsin-Wei Kuo (2007)
10.1056/NEJM198708273170903
Gastrointestinal absorption of calcium from milk and calcium salts.
M. Sheikh (1987)
10.1592/phco.28.8.951
Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
J. Kaye (2008)
10.1136/bmj.321.7261.598
Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism
P. Vestergaard (2000)
10.7326/0003-4819-66-5-917
The absorption of calcium carbonate.
P. Ivanovich (1967)
10.1111/J.1440-1746.2007.05114.X
Epidemiological features of biliary atresia in Taiwan, a national study 1996-2003.
M. Tiao (2008)
10.1007/s007740050017
Epidemiology of cervical and trochanteric fractures of the proximal femur in 1996 in Kaohsiung City, Taiwan
K. Huang (2000)
10.3177/JNSV.44.869
Effect of L-lactic acid on the absorption of calcium in gastrectomized rats.
O. Chonan (1998)
10.1007/s00223-006-0021-7
Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture
P. Vestergaard (2006)
10.1002/PDS.1322
Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003.
Chi-Wen Chiang (2007)
10.1001/JAMA.296.24.2947
Long-term proton pump inhibitor therapy and risk of hip fracture.
Yu-Xiao Yang (2006)
10.1007/BF01352010
Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans
K. Mizunashi (2005)
10.3177/JNSV.44.473
Effect of L-lactic acid on calcium absorption in rats fed omeprazole.
O. Chonan (1998)



This paper is referenced by
10.1002/pds.4406
Proton pump inhibitor use and the risk of fractures among an older adult cohort
Barbara N Harding (2018)
10.1002/PHAR.1007
Fracture risk and bone mineral density reduction associated with proton pump inhibitors.
Yuen Ting Lau (2012)
10.1155/2013/321379
Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy-a 2013 update.
P. Moayyedi (2013)
10.1111/j.1742-1241.2012.02921.x
Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk?
J. Heidelbaugh (2012)
10.1007/s00198-018-4788-y
Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies
T. N. Poly (2018)
10.1586/ecp.11.36
Managing the adverse effects of nonsteroidal anti-inflammatory drugs
P. Patrignani (2011)
10.11005/jbm.2018.25.3.141
Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis
Y. Nassar (2018)
10.1007/s00535-012-0722-9
A population-based case–control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate
J. Lee (2012)
10.1038/s41598-020-70712-9
Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes
Ya-Shuan Chou (2020)
10.1111/j.1365-2982.2011.01873.x
Predictors of acid suppression success in patients with chronic laryngitis.
An Jiang Wang (2012)
10.1097/MD.0000000000000532
Risk Factors and Incidence of Repeat Osteoporotic Fractures Among the Elderly in Taiwan
Peng-Ching Hsiao (2015)
10.1007/s00198-015-3365-x
Proton-pump inhibitors and risk of fractures: an update meta-analysis
B. Zhou (2015)
10.1136/bmj.e372
Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study
H. Khalili (2012)
10.1002/jor.23221
Hypochlorhydria‐induced calcium malabsorption does not affect fracture healing but increases post‐traumatic bone loss in the intact skeleton
M. Haffner-Luntzer (2016)
10.1016/j.bone.2020.115306
Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
J. Park (2020)
10.1016/j.bonr.2019.100204
Higher dose but not low dose proton pump inhibitors are associated with increased risk of subsequent hip fractures after first hip fracture: A nationwide observational cohort study
W. Brozek (2019)
CAG Position Statement: Hip fracture and proton pump inhibitor therapy - a 2013 update
P. Moayyedi (2013)
10.1016/j.annepidem.2014.01.004
Proton-pump inhibitor use and hip fractures in men: a population-based case-control study.
A. Adams (2014)
10.18314/igh.v1i1.1185
Long Term Use of Proton Pump Inhibitors: Where to Draw the Line
Munirul M. Haque (2018)
10.1159/000350638
Administration of Proton Pump Inhibitors and Risk of Systemic Side Effects
Yoshikazu Kinoshita (2013)
10.1053/j.ajkd.2011.10.049
Risk of herpes zoster in patients treated with long-term hemodialysis: a matched cohort study.
Chien-Chun Kuo (2012)
The role of Meta-analysis in Pharmacovigilance: how best to combine different sources of evidence about harms?
Carlos Alves (2014)
10.1177/2042098617715381
Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence
Marina L Maes (2017)
An Expert Review and Recommendations on the Rational Use of Proton Pump Inhibitors: Indian Perspective.
S. Bhatia (2019)
10.1053/j.gastro.2017.04.047
Complications of Proton Pump Inhibitor Therapy.
M. vaezi (2017)
10.1177/1759720X12444710
DUEXIS® (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug
A. Bello (2012)
Bone Mineral Density 1 The Effect of Omeprazole on Bone Mineral Density in Wistar Rats
Layla (2017)
10.1111/cts.12475
A Proton Pump Inhibitor in the Reformulation Setting: Bioequivalence and Potential Implications for Long‐Term Safety
E. Dubcenco (2017)
10.1007/s00296-018-4142-x
Proton pump inhibitors’ use and risk of hip fracture: a systematic review and meta-analysis
Salman Hussain (2018)
10.1370/afm.1243
Use of Acid-Suppressive Drugs and Risk of Fracture: A Meta-analysis of Observational Studies
Chun-Sick Eom (2011)
An updated meta-analysis : the effect of proton pump inhibitor on risk of osteoporosis and fracture
Xiu-De Fan (2017)
10.1002/pds.2350
Factors associated with the initiation of proton pump inhibitors in corticosteroid users.
J. Munson (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar